Picture of Hanson Sarah

Sarah Hanson

Co-Chair Life Sciences & Healthcare Sector

CMS Cameron McKenna Nabarro Olswang LLP
Cannon Place
78 Cannon Street
United Kingdom
Languages English

Sarah Hanson is a Partner in the Technology team and is the UK representative for the management committee of the CMS Commercial Group. She works across a number of sectors but has a particular focus on life sciences & healthcare and consumer products.  She is Co-chair of the UK Life Sciences & Healthcare Sector Group.

She has specialised in high value, cross-border commercial, intellectual property and outsourcing transactions for more than 20 years having advised on a broad range of commercial agreements relating to in and out licensing, sales and distributor arrangements, research and development, manufacturing and supply, strategic alliances and joint ventures.  During her time with the firm she has been on secondment with Warner Lambert (now part of Pfizer). 

more less

Sarah was also the exclusive winner of the Healthcare and Lifescience category for the UK of the International Law Office (ILO) Client Choice Awards.

Client Choice Awards

Sarah is ranked in Band 2 as a leading practitioner in the Lifesciences – Transactional category in Chambers where sources say she is “rock solid and praise her for her commercial approach” (2016 edition).

"Sarah is ranked as a leading practitioner for licensing work on the basis that she “has forged a strong name in transactions for patent-rich practitioners”."

IAM 1000 top patent practitioners.

Sarah has been recommended in a number of directories including PLC which Lawyer? Lifesciences the PLC Lifesciences Handbook and Legal 500 that described her as “delightful, very responsive and helpful”.

Sarah is ranked as a leading individual in Who’s Who Legal: Lifesciences – Transactional (2016 edition).

Relevant experience

  • Almirall SA on the transfer of its respiratory franchise to AstraZeneca for an initial consideration of USD 875m on completion and up to USD 1.22bn in development, launch and sales related milestone payments.
  • PGT Healthcare LLP in relation to a collaboration with Swisse Wellness Group Party Limited in relation to vitamin, mineral and food supplement products across certain territories.
  • Sinclair IS Pharma plc on an exclusive 100 year distribution arrangement with an affiliate of Valeant Pharmaceuticals International, Inc, for injectable aesthetic dermal filler products in Western Europe.
  • Takeda Pharmaceutical on its EUR 9.6bn (debt-free cash free) acquisition of Swiss drug company, Nycomed.
  • A retail company in relation to a comprehensive IT transformation project with a value of between GBP 1-2bn.  The new IT operating model involves the appointment of a ‘service integrator’ supplier who will manage and integrate all IT services.  The project also involves appointment of multiple IT “service tower” providers.  This includes the following IT services: (i) End User Computing services; (ii) Network services (telecoms networks across company’s entire estate); (iii) Front Office services (front office IT applications including cash and stock management, retail and stock sales, branch accounting); and (iv) Back Office services (back office IT applications including HR, accounting and finance systems).
  • Futura Medical, an AIM listed company, in relation to the licensing of its CSD500 product to major pharmaceutical and healthcare group, including Church & Dwight and Ansell.  We have advised on the commercial agreements with contract manufacturers and own brand labellers as well as the associated technical and quality agreements.
  • Camelot in respect of the establishment of the Euro Millions lottery and related matters.
  • On the establishment of the Francis Crick Institute, a consortium of Cancer Research UK, the MRC, UCL and the Wellcome Trust, as a world leading establishment for medical research and innovation at Kings Cross, London, together with ongoing operational advice.
  • Nestlé Health Science on its licence agreement with Lipid Therapeutics for exclusive rights to develop and commercialise a new therapeutic for treating mild to moderate ulcerative colitis.
  • hVIVO plc, an AIM listed company, on its interests in PrEP Biopharm and also on PrEP Biopharm’s licensing arrangements with Janssen Pharmaceuticals with respect to technologies to be developed and commercialised for the treatment of a variety of respiratory viruses.
more less


  • 2004 – Intellectual Property Diploma, Bristol University, Bristol
  • 1994 – Distinction, The College of Law, LPC, Chester
  • 1993 – BA (Hons) Cantab Law 2:1, St John’s College, Cambridge
more less


  • ABHI
  • ABPI
  • Biotech Industry Association
  • Society for Computers & Law
  • TechUK
more less


  • European Biopharmaceutical Review – eHealth opportunities for the biopharmaceutical industry
more less

Lectures list

  • EU Pharma Law Conference – May 2015
more less


Show only
11 January 2017
Food and bever­age
20 Jun 18
In­nov­a­tion in the Cloud - Re­du­cing IP Risk for the...
Im­pact of Brexit on the Phar­ma­ceut­ic­al Sec­tor
On 17 May 2018, the Busi­ness, En­ergy and In­dus­tri­al Strategy Com­mit­tee (the "Com­mit­tee") pub­lished its re­port: "The Im­pact of Brexit on the phar­ma­ceut­ic­al sec­tor" (the "Re­port"). The full re­port can be found here.
Our ehealth cap­ab­il­it­ies
Brexit: Life Sci­ences - House of Com­mons Is­sues Re­port
On 21 March 2018, the UK House of Com­mons Health and So­cial Care Com­mit­tee pub­lished a re­port out­lining its re­com­mend­a­tions to the Gov­ern­ment in re­la­tion to Brexit ne­go­ti­ations with the EU and the im­pact of Brexit on medi­cines, med­ic­al devices and sub­stances.
CMS Glob­al Lifes­ci­ences For­um 2015
Shap­ing the fu­ture through in­nov­a­tion and col­lab­or­a­tion
Life Sci­ences In­dus­tri­al Strategy
Last week saw the launch of the Gov­ern­ment's In­dus­tri­al Strategy white pa­per, high­light­ing five key areas of fo­cus for per­form­ance im­prove­ment in the UK and set­ting out a roadmap for UK busi­ness, to boost pro­ductiv­ity and earn­ing power.
CMS Glob­al Lifes­ci­ences For­um Re­port 2015
Brexit: State of play for Life Sci­ences com­pan­ies
With the UK pre­par­ing to leave the European Uni­on (EU) on 30 March 2019, life sci­ences com­pan­ies are plan­ning ahead for changes to the busi­ness and reg­u­lat­ory en­vir­on­ment. Dis­cus­sions at the EU Sum­mit on 19 Oc­to­ber 2017 primar­ily fo­cused on what are re­garded.
The An­ti­dote - Winter 2015
EU Med­ic­al Devices Reg­u­la­tion and In-Vitro Med­ic­al Devices Reg­u­la­tion...
The EU Med­ic­al Devices Reg­u­la­tion and In-Vitro Med­ic­al Devices Reg­u­la­tion (the “Reg­u­la­tions”) were ad­op­ted on 5 April 2017, fol­low­ing a fi­nal vote at the European Par­lia­ment. The Reg­u­la­tions were pro­posed by the Com­mis­sion in 2012 (as dis­cussed in our pre­vi­ous.
Con­nect: CMS Alumni An­nu­al Re­view 2014
EMA & HMA es­tab­lish task force to ex­plore big data's po­ten­tial for...
A new task force has been set up to ex­plore how medi­cines reg­u­lat­ors in the EU can use big data to im­prove hu­man and an­im­al health. The task force has been es­tab­lished by the European Medi­cines Agency (“EMA”), in con­junc­tion with the EEA Heads of Medi­cines.
Sup­port­ing your busi­ness
The An­ti­dote - Spring 2014
Tak­ing a look at "pharm­er­ging" mar­kets and the re­sur­gence...
CMS re­tail sec­tor
Health and beauty
The An­ti­dote - Pre­dic­tions for the Lifes­ci­ences sec­tor...